Q2 Earnings Forecast for EWTX Issued By HC Wainwright

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Stock analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Edgewise Therapeutics in a report released on Monday, June 30th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($0.41) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Edgewise Therapeutics’ Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($1.93) EPS, FY2028 earnings at ($0.97) EPS and FY2029 earnings at $3.10 EPS.

A number of other research analysts also recently commented on EWTX. Guggenheim started coverage on Edgewise Therapeutics in a report on Wednesday, April 30th. They issued a “buy” rating and a $41.00 price target for the company. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $48.00 target price on shares of Edgewise Therapeutics in a report on Thursday, June 5th. Scotiabank cut Edgewise Therapeutics from a “sector outperform” rating to a “sector perform” rating and dropped their price target for the stock from $50.00 to $14.00 in a research report on Wednesday, April 2nd. Piper Sandler restated an “overweight” rating and issued a $51.00 target price on shares of Edgewise Therapeutics in a research report on Wednesday, April 2nd. Finally, Wedbush restated an “outperform” rating and issued a $43.00 target price on shares of Edgewise Therapeutics in a research report on Monday, April 21st. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $40.00.

Edgewise Therapeutics Price Performance

Shares of NASDAQ:EWTX opened at $13.01 on Wednesday. The firm has a market capitalization of $1.37 billion, a PE ratio of -8.39 and a beta of 0.25. The business has a 50-day moving average of $14.71 and a two-hundred day moving average of $20.82. Edgewise Therapeutics has a 12 month low of $10.60 and a 12 month high of $38.12.

Edgewise Therapeutics (NASDAQ:EWTX) last released its earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.02.

Institutional Investors Weigh In On Edgewise Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Diadema Partners LP bought a new stake in shares of Edgewise Therapeutics in the fourth quarter worth about $36,000. Jones Financial Companies Lllp bought a new position in shares of Edgewise Therapeutics during the first quarter worth about $47,000. GF Fund Management CO. LTD. acquired a new position in Edgewise Therapeutics during the fourth quarter valued at approximately $53,000. Allostery Investments LP acquired a new position in Edgewise Therapeutics during the first quarter valued at approximately $66,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in Edgewise Therapeutics by 55.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,194 shares of the company’s stock valued at $70,000 after purchasing an additional 1,141 shares during the last quarter.

Insider Buying and Selling

In other news, General Counsel John R. Moore sold 1,930 shares of the company’s stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $16.45, for a total transaction of $31,748.50. Following the transaction, the general counsel owned 6,531 shares of the company’s stock, valued at $107,434.95. This represents a 22.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin Koch sold 4,276 shares of the company’s stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $16.45, for a total value of $70,340.20. Following the transaction, the chief executive officer directly owned 20,619 shares in the company, valued at $339,182.55. This trade represents a 17.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,258 shares of company stock valued at $234,544 over the last ninety days. Company insiders own 23.20% of the company’s stock.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.